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Rhenium mixed-ligand complexes with S,N,S-tridentate
thiosemicarbazone/thiosemicarbazide ligands†
Pedro I. da S. Maia,a Hung Huy Nguyen,b Adelheid Hagenbach,c Silke Bergemann,d
Ronald Gust,e Victor M. Deﬂona and Ulrich Abram*c
Rhenium(V) complexes containing tridentate thiosemicarbazones/thiosemicarbazides (H2L1) derived
from N-[N’,N’-dialkylamino(thiocarbonyl)]benzimidoyl chlorides with 4,4-dialkylthiosemicarbazides have
been synthesized by ligand-exchange reactions starting from [ReOCl(L1)]. The chlorido ligand of [ReOCl-
(L1)] (4) is readily replaced and reactions with ammonium thiocyanate or potassium cyanide give [ReO-
(NCS)(L1)] (6) and [ReO(CN)(L1)] (7), respectively. The reaction of (NBu4)[ReOCl4] with H2L1 and two
equivalents of ammonium thiocyanate, however, gives in a one-pot reaction [ReO(NCS)2(HL1)] (8), in
which the pro-ligand H2L1 is only singly deprotonated. An oxo-bridged, dimeric nitridorhenium(V) com-
pound of the composition [{ReN(HL1)}2O] (11) is obtained from a reaction of (NBu4)[ReOCl4], H2L1 and
sodium azide. The six-coordinate complexes [ReO(L1)(Ph2btu)] (12), where HPh2btu is N,N-diphenyl-N’-
benzoylthiourea, can be obtained by treatment of [ReOCl(L1)] with HPh2btu in the presence of NEt3.
Studies of the antiproliferative eﬀects of the [ReOX(L1)] system (X = Cl−, NCS− or CN−) on breast cancer
cells show that the lability of a monodentate ligand seems to play a key role in the cytotoxic activity of




Thiosemicarbazones and their transition metal complexes are
versatile compounds and some of them possess remarkable
biological and pharmaceutical properties including anti-neo-
plastic activity.1–6 Relatively less is known about thiosemi-
carbazones with rhenium and technetium. This is surprising
since some of the hitherto explored compounds have shown
that they are able to stabilize the {MVvO}3+ and M3+ (M = Re,
Tc) cores, which are readily accessible by reduction of [MO4]
−
ions from commercial isotope generator systems with
common reducing agents. This makes them interesting as
ligands in future radiopharmaceutical agents, since the two
β−-emitting isotopes, 188Re and 186Re, have potential to be
used in radioimmunotherapy,7–9 while the radionuclide 99mTc
is widely used in diagnostic nuclear medicine.10–13 Addition-
ally, some of the hitherto isolated thiosemicarbazone com-
plexes of rhenium possess intrinsic anticancer properties, but
the molecular mechanism of interaction is not yet known.14,15
Surprisingly, the first structural report on rhenium thio-
semicarbazone complexes was published only in 2003 dealing
with cationic ReIII compounds of the general composition
[ReIII(L)2]
+ (1, Chart 1), with HL = 2-acetylpyridine thiosemicar-
bazones. They were prepared by a reductive ligand exchange
Chart 1 Rhenium complexes with thiosemicarbazones (for details see ref.
14–19).
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starting from [ReOCl3(PPh3)2] or perrhenate.
16 However, a
number of undesired side-reactions complicated the isolation
of higher amounts of pure products in such procedures. The
stabilization of oxorhenium(V) complexes of the composition
[ReOCl2(L)] (2) succeeded with HL = 2-acetylpyridineform-
amide thiosemicarbazones.17 Reduction of the metal ion and
the formation of ReIII complexes, here, occur only when an
excess of thiosemicarbazones is used and the reaction is per-
formed for a prolonged period of time.17 Very recently, a cat-
ionic rhenium(V) complex of the composition [Re(L)]+ (3) with
a hexadentate bis(thiosemicarbazone) ligand (H4L) was pre-
pared.18 Compound 3 represents a rare example of a
rhenium(V) complex, which does not contain one of the ReO3+,
ReN2+ or Re(NPh)3+ cores, but coordinates the hexadentate
ligand with a distorted trigonal prismatic coordination sphere.
In previous papers we reported some representatives of a
new class of rhenium(V) and technetium(V) complexes with tri-
dentate thiosemicarbazones/thiosemicarbazides (H2L1), which
contain an additional thiourea binding site.14 They stabilize
the MO3+ (M = Re and Tc) as well as ReN2+ cores upon for-
mation of complexes of the compositions [MOCl(L1)] (M = Re:
4) and [ReN(L1)(PPh3)] (5), respectively. A significant cell
growth inhibition of human MCF-7 breast cancer cells was
observed in in vitro experiments for several representatives of
H2L1 and their oxorhenium(V) complexes [ReOCl(L1)].
15 No
clear structure–activity relationship (SAR) of compounds 4 was
observed when the periphery of the thiosemicarbazones was
modified (neither in the positions R1 and R2 nor in the pos-
itions R3 and R4), while the replacement of the O2− ligand by
a nitrido N3− ligand and the chlorido ligand by a triphenyl-
phosphine (compound 5 in Chart 1) terminates the cytotoxicity
of the complexes.
In the present communication, we describe the ligand
exchange chemistry of [ReOCl(L1)] complexes together with
some evaluation of the biological activity of the reaction pro-
ducts. Two ligands with methyl/phenyl (H2L1a) and hexa-
methylene (H2L1b) residues (see Chart 2) in the
thiosemicarbazone binding site have been used throughout
the experiments, while the thiourea binding site was kept
unchanged with two ethyl residues.
Results and discussions
The chlorido ligand in the [ReOCl(L1)] complexes is
suﬃciently labile to allow ligand exchange reactions under
mild conditions. Reactions of [ReOCl(L1)] with ammonium
thiocyanate or potassium cyanide in MeOH–CH2Cl2 give red
complexes of the types [ReO(NCS)(L1)] (6) and [ReO(CN)(L1)]
(7) (Scheme 1), respectively, in high yields. Attempts to prepare
the analogous isoselenocyanato compound failed, since the
corresponding reaction with KSeCN resulted in the precipi-
tation of elemental selenium and only the cyanido complexes
[ReO(CN)(L1)] could be isolated in medium yields. The pro-
ducts are readily soluble in CH2Cl2 and only sparingly soluble
in MeOH.
The IR spectra of isothiocyanato derivatives 6 show strong
bands around 2060 cm−1, which is in accord with the coordi-
nation through the nitrogen atoms of isothiocyanato ligands.19
N-coordination of the NCS− is found for the majority of
rhenium complexes with this ligand.20 The ν(CN) stretches in
the IR spectra of the complexes 7 are detected as weak bands
in the 2120–2130 cm−1 region. These observations are in agree-
ment with the fact that the CN− ion is a better σ-donor than a
π-acceptor. Thus, a shift to higher wavenumbers of the ν(CN)
frequency with regard to uncoordinated cyanide (2080 cm−1) is
observed when electrons are removed from the 5σ orbital,
which is weakly antibonding.19 Furthermore, the strong RevO
vibrations are observed around 975 and 990 cm−1 for the
[ReO(NCS)(L1)] and [ReO(CN)(L1)] complexes, respectively.
The 1H NMR spectra of 6 and 7 are expectedly very similar
to those of [ReOCl(L1)]. The ESI+ MS spectra of all compounds
show the molecular ion peaks. While these peaks are the exclu-
sive high-mass peaks in the spectra of the cyanido com-
pounds, the spectra of the [ReO(NCS)(L1)] show additional
intense peaks for ions, which can be attributed to [ReO(L1)]+.
This indicates relatively weak Re–N bonds.
X-ray structure analyses confirm the spectroscopic data.
Fig. 1a illustrates the molecular structure of 6a as a representa-
tive of the [ReO(NCS)(L1)] complexes. Selected bond lengths
and angles for this compound are shown together with the
values for 6b (not shown) in Table 1. The asymmetric unit of
6a contains two molecules, which are diﬀerent in the orien-
tation of their two ethyl residues. In one of the molecules the
ethyl groups are positioned in the same direction as the RevO
bond, while in the second one they point to the opposite
direction. Fig. 1b illustrates the molecular structure of
[ReO(CN)(L1a)] (7a) as a representative compound of the
cyanido derivatives. For all three studied complexes, the
coordination environments of the rhenium atoms are best
described as distorted square pyramids, where the oxo ligands
occupy the apical positions and the basal planes are defined
by the donor atoms of the tridentate thiosemicarbazone
Chart 2 Thiosemicarbazone ligands used in this study.
Scheme 1 Reactions of [ReOCl(L1)] with pseudohalides.
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ligands and the donor atom of the pseudohalide. Five-coordi-
nation is not rare in the coordination chemistry of oxorhenium(V)
or nitridorhenium(V) complexes,20 and is due to the strong
and space-filling π-donors O2− and N3−. Their coordination
results in increased O/N-M-(equatorial) donor atom angles.
This is also observed in the examples of the present communi-
cation, where values between 103.6(3) and 113.7(2)° are
observed (Table 1). Consequently, the rhenium atoms are situ-
ated above the least square planes of the equatorial donors
(0.769(3) and 0.767(3) Å for 6a, 0.679(6) Å for 6b and 0.721(2) Å
for 7a). In the isothiocyanato complexes, the CS bonds in the
isothiocyanato ligands are shorter than those in the thiosemi-
carbazonato ion, which is indicative of a delocalization of
π-electron density inside the almost linear NCS− ligand. Both
the Re–CN and Re–NCS bond lengths are around 2.05 Å.
In the complexes discussed above, in the rhenium(V) com-
plexes of ref. 15 as well as in the corresponding Au(III) com-
plexes of the composition [AuCl(L1)],22 the tridentate ligands
are always doubly deprotonated, which provides an optimal
charge compensation. During reactions with M2+ ions, such as
Ni2+, Pd2+ or Pt2+, however, H2L1 ligands form square-planar
complexes of the same topology ([MCl(HL1)]), but with one
deprotonation only. Thus, they are obviously able to act in
accordance with the charge requirements of the metal com-
plexes formed. This has also been observed for isothiocyanato
complexes with the oxorhenium(V) core. While the five-coordi-
nate compounds [ReO(NCS)(L1)] described above are results of
Cl−/NCS− ligand exchange reactions and do not undergo
further reactions even with an excess of SCN−, another reac-
tion pathway is observed when the reaction conditions are
modified.23 One-pot reactions of (NBu4)[ReOCl4] with H2L1b
and an excess of NH4SCN reproducibly result in a brown
complex of the composition [ReO(NCS)2(HL1b)] (8b), in which
only a single deprotonation of the chelator is observed. The
reaction is almost quantitative. The resulting neutral complex
is readily soluble in CH2Cl2 or CHCl3, but almost insoluble in
alcohols (Scheme 2).
The IR spectrum of 8b expectedly shows signals of two
NCS− ligands with considerably diﬀerent bonding positions,
which is finally confirmed by the results of an X-ray structure
analysis. The RevO stretching vibration is observed at
965 cm−1, which is hypsochromically shifted by 15 cm−1 with
respect to the value in the IR spectrum of 6b. This can be
explained by the occupation of the coordination position trans
to the oxido ligand by another NCS−. The weaker bond to the
axial NCS− ligand is also confirmed by X-ray diﬀraction (Re–N6
Table 1 Selected bond lengths (Å) and angles (°) for [ReO(NCS)(L1a)]a (6a),
[ReO(NCS)(L1b)] (6b) and [ReO(CN)(L1a)] (7a)
6a 6b 7a
Re–O10 1.664(6)/1.670(6) 1.65(2) 1.686(5)
Re–S1 2.310(2)/2.313(2) 2.293(8) 2.295(2)
Re–S2 2.275(2)/2.271(2) 2.278(4) 2.285(2)
Re–N2 1.982(5)/1.999(6) 2.05(1) 2.023(5)
Re–N6 2.045(6)/2.040(7) 2.07(2)
Re–C4 2.051(8)
S1–C1 1.753(8)/1.738(8) 1.79(2) 1.751(7)
C1–N1 1.343(9)/1.345(9) 1.29(3) 1.337(8)
N1–C2 1.308(9)/1.325(9) 1.33(2) 1.314(7)
C2–N2 1.380(9)/1.368(9) 1.33(2) 1.352(8)
N2–N3 1.415(8)/1.416(8) 1.40(2) 1.411(7)
N3–C3 1.29(1)/1.28(1) 1.30(2) 1.298(8)
S2–C3 1.777(7)/1.785(7) 1.79(2) 1.765(7)
C3–N4 1.36(1)/1.36(1) 1.30(2) 1.367(8)
O10–Re–S1 112.4(2)/112.6(2) 109.5(5) 112.2(2)
O10–Re–N2 104.6(3)/104.0(3) 108.4(7) 107.9(2)
O10–Re–S2 113.7(2)/113.3(2) 110.4(5) 113.4(2)
O10–Re–N6 104.6(3)/104.4(3) 104.8(9)
O10–Re–C4 103.6(3)
a Values for two crystallographically independent molecules.
Scheme 2 Formation of [ReO(NCS)2(HL1b)] (8b) and [ReO(NCS)(DMSO)(L1b)]
(9b).
Fig. 1 Ellipsoid representations of the molecular structures of (a) [ReO(NCS)-
(L1a)] (6a) and (b) [ReO(CN)(L1a)] (7a).21 Hydrogen atoms have been omitted
for clarity.
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bond: 2.10(1) Å vs. Re–N7: 2.21(1) Å). Fig. 2a depicts the mole-
cular structure of 8b. Table 2 summarizes selected bond
lengths and angles. It can clearly be seen that the bonding
situation in the complex is changed by the increase of the
coordination number. The O10–Re–N/S angles to the donor
atoms of the equatorial coordination sphere decrease and,
thus, the rhenium atom is shifted out of the equatorial coordi-
nation plane by 0.283(5) Å towards the oxido ligand. But also
the bond lengths inside the chelating ligand are changed as a
consequence of the protonation of N3. The C3–N3 bond, but
also the C–S bonds are lengthened with respect to 6b.
The lability of the NCS− ligand in trans position to the
oxido ligand in [ReO(NCS)2(HL1b)] (8b) is demonstrated by the
formation of [ReO(NCS)(dmso-κO)(L1b)] (9b), when the bis-iso-
thiocyanato compound is recrystallized from DMSO. The repla-
cement of the anionic ligand NCS− by a neutral dmso ligand
in trans position to the oxido ligand goes along with a second
deprotonation of the organic ligand in 8b. This type of reaction
underlines the flexibility of the tridentate H2L ligands to act as
mono- or dianionic chelators in dependence on the require-
ments of the coordinated metal ions. Such behaviour has also
been observed with other metal ions before as discussed
above. The solid state structure of 8b contains hydrogen bonds
between N3 and the sulfur atom of the NCS− ligand in trans
position of the oxido ligand (see Fig. 2b), and thus, pre-formed
HSCN. Despite the fact that this is an intermolecular hydrogen
bond and only present in the solid state, it cannot be excluded
that the related weakening of the Re–N7 bond supports the
abstraction of HSCN during the dissolution of 8b in DMSO.
The molecular structure of 9b is shown in Fig. 3. Selected
bond lengths and angles are compared to the corresponding
values of 8b in Table 2. The second deprotonation of the
organic ligands causes the re-formation of an extended
π-system with C–N and C–S bond lengths being between the
values expected for the respective single or double bonds. The
dmso ligand is O-bonded as in almost all of the few struc-
turally characterized dmso complexes of rhenium.25–30 The
only exception, where an S-bonded dmso ligand has unam-
biguously been found in a rhenium compound, is the organo-
metallic complex [Re(NO)(cp)(PPh3)(dmso-κS)]+.31
























a Values for two crystallographically independent species.
Fig. 3 Ellipsoid representations of the molecular structure of [ReO(NCS)(dmso-
κO)(L1b)] (9b).21 Hydrogen atoms have been omitted for clarity.
Fig. 2 (a) Ellipsoid representations of the molecular structure of [ReO-
(NCS)2(HL1b)] (8b).
21 Hydrogen atoms on carbon atoms have been omitted for
clarity. (b) Hydrogen bonding: N3⋯S7’ 3.261 Å, N3–H3⋯S7’ 144.6°, symmetry
operation (’): x + 3/2, y − 1/2, −z + 1/2).24
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The exchange of the chlorido ligand in [ReOCl(L1b)] can
also be performed by an azido one. The resulting product
[ReO(N3)(L1b)] (10b) can be isolated from two reactions: (i) the
ligand exchange starting from [ReOCl(L1b)] with sodium azide
in a CH2Cl2–MeOH mixture or (ii) by a one-pot reaction start-
ing from (NBu4)[ReOCl4], NaN3 and H2L1b in MeOH
(Scheme 3). The product precipitates as a brown solid in both
cases. The IR spectrum of 10b shows the ν(RevO) vibration at
972 cm−1 and a strong band related to ν(NuN) at 2059 cm
−1,
which is in the expected range for an azido ligand in the equa-
torial plane of a rhenium(V) complex.32 In solution, however,
10b is not stable and the formation of a nitrido species is
observed. For this reason, method B is recommended for the
synthesis of 10b. The formation of HCl during the synthesis
according to method A may facilitate the conversion into the
nitrido complex. The conversion of the azido compound into a
nitrido complex proceeds even at room temperature and also
prevents the recording of NMR spectra of suﬃcient quality.
After recrystallization from CH2Cl2–MeOH or CH2Cl2–MeCN,
deep red crystals of the composition [{ReN(HL1b)}2(O)] (11b)
are obtained. In the IR spectrum of these crystals no more
ν(RevO) and ν(NuN) vibrations are present, but a new band at
694 cm−1 indicates the possible formation of a μ-oxo dimeric
complex. A band at 1028 cm−1 can be assigned to the ν(ReuN)
vibration.33,34
The decomposition of nitrido ligands or other nitrogen-con-
taining ligands with final formation of nitrido complexes has
been described for many examples,35–37 and particularly the
decomposition of azido compounds is a convenient approach,
e.g. to prepare the common nitrido precursor (NBu4)-
[ReNCl4].
38
The nature of 11b as an oxo-bridged dimer is confirmed by
the high resolution mass spectrometry and X-ray diﬀraction.
The ESI+ MS spectrum of the complex clearly presents the
molecular ion peak of the nitrido complex at m/z = 1198.2446
(m/z (calcd) = 1198.2698) instead of the oxo ligand (m/z (calcd)
= 1200.2378). Fig. 4 shows the molecular structure of the
complex, which possesses inversion symmetry with the oxygen
atom as a centre of inversion. Selected bond lengths and
angles are contained in Table 3. The rhenium atoms are five-
coordinate, which is a frequent finding in the chemistry of
nitridorhenium(V) complexes and readily explained by the
strong trans influence of the terminal nitrido ligand. The
coordination mode of the chelating ligand is unexceptional
and similar to that in 8b. The bridging oxido ligand originates
from residual water in the solvent used. Similar reaction pat-
terns have been observed before for other oxorhenium(V)
complexes.20
The formation of oxo bridges in cis arrangement to a
nitrido ligand is not without precedence in the coordination
chemistry of rhenium, but is hitherto restricted to one
example of a Re(V) complex and some Re(VII) compounds.39,40
A few more examples are known for the lighter homologous
element technetium, which possesses a more extended nitrido
chemistry, and where the {NTcO2TcN}
2+ unit represents a core
structure of the Tc(VI) chemistry.41–44
The formation of “3 + 2” mixed ligand complexes could be
achieved by reacting [ReOCl(L1)] complexes with N,N-diphenyl-
benzoylthiourea, HPh2btu, in a mixture of CH2Cl2 and MeOH
(Scheme 4). The bidentate benzoylthiourea has been chosen
for such experiments as a representative for other bidentate,
monoanionic ligands. We have recently studied the coordi-
nation chemistry of these O,S ligands with several rhenium
and technetium precursors extensively and could show that
Fig. 4 Ellipsoid representations of the molecular structure of [{ReN(HL1b)}2(O)]
(11b).21 Hydrogen atoms have been omitted for clarity.
Table 3 Selected bond lengths (Å) and angles (°) for 11b
Re–N10 1.676(5) C1–N1 1.316(7)
Re–S1 2.333(2) N1–C2 1.332(6)
Re–S2 2.315(1) C2–N2 1.325(6)
Re–N2 2.119(1) N2–N3 1.418(6)
Re–O 1.829(1) N3–C3 1.272(7)
S1–C1 1.737(6) C3–S2 1.769(5)
N10–Re–S1 110.6(2) S1–Re–N2 87.7(1)
N10–Re–N2 102.7(2) S1–Re–O 83.98(4)
N10–Re–S2 110.7(2) S2–Re–N2 80.0(1)
N10–Re–O 106.7(2) S2–Re–O 87.71(3)
S1–Re–S2 138.55(5) N2–Re–O 150.5(1)
Scheme 3 Formation of [{ReN(HL1b)}2O] (11b).
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they form stable complexes with diﬀerent oxorhenium(V) cores
including “3 + 2” mixed-ligand compounds.45–49 The reactions,
which can simply be performed in a one-pot version without
the isolation of the [ReOCl(L1)] complexes, result in purple
solids of the general composition [ReO(L1)(Ph2btu)] (12).
The IR spectra of the complexes 12 exhibit ν(RevO) frequen-
cies around 970 cm−1. The ν(CvO) band of the benzoylthiourea
(1690 cm−1) shows a strong bathochromic shift as a conse-
quence of chelate formation as has been discussed pre-
viously.45 They appear in the spectra of the mixed-ligand
complexes at approximately 1500 cm−1. The mass spectra of
the complexes show the expected molecular ion peaks without
any ligand dissociation or formation of oligomeric complexes.
Fig. 5 depicts the molecular structure of 12b as a model
compound for this kind of complex and selected bond lengths
can be found in Table 4. The RevO distance of 1.659(5) Å is
within the expected range for a rhenium–oxygen double
bond.20 A distorted octahedral coordination geometry is found
for this compound, with the oxido ligand and the oxygen atom
of the bidentate Ph2btu
− ligand in trans position to each other.
The tridentate thiosemicarbazone (L1)2− occupies three pos-
itions in the equatorial plane, which is completed by the
sulfur atom of benzoylthiourea. The rhenium atom is situated
0.408(2) Å above this plane towards the oxido ligand. This
value is less than those for the five-coordinate compounds dis-
cussed above (values between 0.68 and 0.77 Å), but more than
that of the also six-coordinate compound 8b (0.28 Å). This
should have some implications on the nature of the Re–O2
bond. And indeed, the Re–O2 bond of 2.223(5) Å belongs to
the longest rhenium–oxygen bonds which have been found for
ligands coordinated in trans position to an oxido ligand in ReV
complexes. Similar values have previously only been reported
for some complexes with small monodentate neutral ligands
such as H2O, MeOH or Me2CO,
20 and “3 + 2” mixed-ligand
complexes with tridentate thiocarbamoylbenzamidines and
bidentate benzoylthioureas, the structure of which is very close
to that of type 12.47 This means that an electron transfer from
the RevO double bond to a trans-Re–O single bond, which is
frequently observed for alkoxido-type ligands,48–52 does not
apply for the compounds under study.
The syntheses of a number of oxorhenium(V) mixed-ligand
complexes with the S,N,S-tridentate thiosemicarbazones
H2L1 have demonstrated the synthetic potential of this class of
ligands and recommend them for analogous studies with tech-
netium. But in addition to this ‘chemical’ point of view, there
is an ongoing interest in the biological behavior of these com-
plexes, since previous studies have shown that the uncoordi-
nated thiosemicarbazones H2L1 as well as their rhenium
complexes [ReOCl(L1)] cause a significant reduction of the
growth of human MCF-7 breast cancer cells.15 The mechanism
of action of some thiosemicarbazones is assumed to be due to
the inhibition of ribonucleotide reductase (RR) interfering
with DNA synthesis and repair, leading to apoptosis.51 The
cytotoxic properties of the complex compounds under study
should be influenced by chelation as well as the composition
and stability of the coordination sphere of the metal.
It was found for the non-coordinated thiosemicarbazones
as well as for their complexes that substitutions of the organic
residues R1 to R4 (see compounds 4 and 5 in Chart 1) do influ-
ence the biological activity dramatically. Some of the com-
plexes have a lower activity, which might possibly be a hint for
diﬀerent uptake and distribution mechanisms for the organic
compounds and their metal complexes. The replacement of
the chlorido ligand (by PPh3) and the oxido ligand by a nitrido
ligand, however, terminates the cytotoxicity of the complexes
completely.15 Square planar gold(III) complexes of the compo-
sition [AuX(L1)] (X = Cl, NCS) show cytotoxic eﬀects against
human MCF-7 cells in the same magnitude as the [ReOCl(L1)]
compounds, while the activity increases significantly when X =
CN.22 This makes it interesting to learn more about the poten-
tial biological activity of the mixed-ligand complexes of the
present study.
Fig. 5 Ellipsoid representations of the molecular structure of [ReO(L1b)-
(Ph2btu)] (12b).
21 Hydrogen atoms have been omitted for clarity.
Scheme 4 Formation of the “3 + 2” mixed-ligand complexes.
Table 4 Selected bond lengths (Å) and angles (°) for [ReO(L1b)(Ph2btu)]
Re–O10 1.674(6) S1–C1 1.733(8)
Re–S1 2.351(2) S2–C3 1.750(9)
Re–S2 2.232(2) S3–C11 1.760(7)
Re–N2 2.040(6) O2–C8 1.267(8)
Re–O2 2.223(5) N1–C2 1.31(1)
Re–S3 2.405(2) N2–C2 1.32(1)
O10–Re–S1 101.7(1) O10–Re–S3 98.4(2)
O10–Re–N2 102.7(2) Re–O2–C8 130.8(5)
O10–Re–S2 98.6(2) S1–Re–S2 159.71(8)
O10–Re–O2 175.8(2)
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First preliminary results, the cytotoxic eﬀects of the com-
pounds against MCF-7 breast cancer cells as IC50 values, are
summarized in Table 5. All thiosemicarbazones H2L1 and
[ReOX(L1)] (X = Cl, NCS, CN) complexes as well as [ReO-
(NCS)2(HL1b)] possess a remarkable biological activity.
Changes of the alkyl/aryl substituents of the thiosemicarb-
azone part of the organic ligand influence the biological
activity of the ligands or the complexes, but without a clear
trend. Such finding is consistent with the activity of com-
pounds 4 (see Chart 1).15
Replacement of the halide or pseudohalides by the chelat-
ing benzoylthiourea terminates the biological activity. This
may suggest that the presence of a monodentate ligand (or
better the possibility to abstract such a ligand in vivo) is an
important prerequisite for the cytotoxicity of the complexes
under study. This impression is supported by the fact that the
cyanido compounds belong to the most active ones of the
entire group. In the case of ligand H2L1b and the correspond-
ing complex [ReO(CN)(L1b)], we can additionally consider a
significant increase of the cytotoxicity for the cyanido complex.
This may be explained by the combined action of two cytotoxic
species inside the cells. However, further studies concerning
this point and other open questions concerning the biological
activity of the new class of rhenium complexes are required
and are underway in our laboratories. These studies include
the behavior of the complexes in aqueous media, the quest for
the point of attack of the active compounds, the intracellular
targets and the role of the metal ion. Experiments with struc-
tural analogue technetium complexes and/or the radioactive
rhenium isotopes 186Re or 188Re may help to answer the open
questions.
Conclusions
The five-coordinate [ReOCl(L1)] complexes show a rich ligand-
exchange chemistry. Simple halide/pseudohalide exchange
products can be obtained as well as nitrido complexes or
mixed-chelate compounds. The coordination numbers of the
product complexes are controlled by the nature of the ligands
applied and the reaction route.
The cytotoxic behaviour of some of the compounds under
study is remarkable. Preliminary structure–activity-studies
suggest that the observed biological activity is related to the
ability of the complexes to release their anionic monodentate
ligands (Cl−, NCS−, CN−). Most probably, the resulting in situ
generated cationic species are key compounds of the cytotoxic
activity. Further experiments are required to understand
details of the observed activity. Such an understanding,




All chemicals were reagent grade and used without further
purification. The solvents were dried and used freshly distilled
prior to use unless otherwise stated. (NBu4)[ReOCl4] was pre-
pared by a standard procedure.52 The thiosemicarbazones
H2L1a (R
1 = Me, R2 = Ph) and H2L1b (R
1R2 = –(CH2)6) were pre-
pared as reported previously.14,15
Physical measurements
IR spectra were measured as KBr pellets on a Shimadzu IR
Prestige-21 spectrophotometer between 400 and 4000 cm−1.
1H-NMR spectra were taken with a JEOL 400 MHz multinuclear
spectrometer. ESI+ mass spectra were measured with an
Agilent 6210 ESI-TOF (Agilent Technologies). The elemental
analyses of carbon, hydrogen, nitrogen, and sulfur were deter-
mined using a Heraeus vario EL elemental analyzer. The
elemental analyses of the rhenium compounds show syste-
matically too low values for hydrogen and in some cases for
carbon. This might be caused by some hydride and carbide
formation. Such eﬀects have been observed before with
ligands of this type,14,15,22 and do not refer to impure samples.
Thus, we omitted the H analyses from the experimental data
given below. The values of the carbon analyses are uncorrected
and some results of high resolution mass spectra are supplied
in order to verify the identity of the complexes unambiguously.
Syntheses
[ReO(NCS)(L1)] type complexes. NH4SCN (0.075 mmol) dis-
solved in 1 mL MeOH was added to a solution containing
0.05 mmol of [ReOCl(L1)] in 1 mL CH2Cl2. The resulting solu-
tion was stirred for 2 h at room temperature. After this time,
the solvent was completely removed in a vacuum and the
remaining solid was repeatedly washed with MeOH, filtered oﬀ
and dried in a vacuum. Single-crystals suitable for X-ray diﬀrac-
tion were obtained by recrystallization from CH2Cl2–MeOH.
[ReO(NCS)(L1a)] (6a). Color: red. Yield: 82% (27 mg). Anal.
Calcd for C21H23N6OReS3 (657.84): C, 38.3; N, 12.8; S, 14.6.
Found: C, 38.4; N, 12.7; S, 15.2%. IR (νmax/cm
−1): 2068 vs
(CuN, isothiocyanato), 1559 m (CvN, ligand), 976 s (RevO).
1H NMR (CDCl3, ppm): 1.29–1.37 (m, 6H, CH3), 3.32 (s, 3H,
NCH3), 3.88–4.03 (m, 4H, CH2), 7.16–7.22 (m, 3H, Ph), 7.1 (t,
J = 7.6 Hz, 2H, Ph), 7.36–7.45 (m, 3H, Ph), 7.69 (d, J = 6.8 Hz,
2H, Ph). ESI+ MS (m/z, assignment): 600 [M − Cl]+, 682
[M + Na]+, 698 [M + K]+, 1258 [2M − SCN]+.
Table 5 Cytotoxic eﬀects (IC50, μM) with estimated esd’s of ligands H2L1 and
their complexes against MCF-7 cells
Compound H2L1a H2L1b
Ligand 0.85(±0.07)a 2.43(0.28)a
[ReOCl(L1)] (4) 0.41(±0.02)a 1.51(0.17)a
[ReO(SCN)(L1)] (6) 1.7(±0.3) 2.0(0.2)
[ReO(CN)(L1)] (7) 0.6(±0.3) 0.6(0.3)
[ReO(SCN)2(HL1)] (8) — 2.3(0.3)
[ReO(L1)(Ph2btu)] (12) 22.4(±0.3) 376(2)
Cisplatin 1.6(±0.1)
a Values taken from ref. 15.
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[ReO(NCS)(L1b)] (6b). Color: red. Yield: 95% (31 mg). Anal.
Calcd for C22H31N7OReS4 (649.86): C, 37.0; N, 12.9; S, 14.8.
Found: C, 36.9; N, 12.8; S, 14.5%. IR (νmax/cm
−1): 2064 vs
(CuN, isothiocyanato), 1558 vs (CvN, ligand), 980 s (RevO).
1H NMR (CDCl3, ppm): 1.27–1.36 (m, 6H, CH3), 1.46–1.59 (m,
8H, CH2 azepine), 3.51–3.61 (m, 4H, N–CH2 azepine),
3.87–3.94 (m, 4H, CH2), 7.19–7.38 (m, 3H, Ph), 7.60 (d, J = 8.0
Hz, 2H, Ph). ESI+ MS (m/z, assignment): 624 [M − Cl + MeOH]+
+ 652 [M + H]+, 674 [M + Na]+, 690 [M + K]+.
[ReO(CN)(L1)] type complexes. KCN (0.075 mmol) dissolved
in 2 mL MeOH was added to a solution containing the desired
[ReOCl(L1)] complex (0.05 mmol) in 1 mL CH2Cl2. The result-
ing mixture was stirred for 2 h at room temperature. After
removal of the solvents in a vacuum, the resulting solid was
dispersed in 2 mL water and extracted with CH2Cl2 (2 × 2 mL).
The organic phase was separated, dried with MgSO4 and the
solvent was removed under reduced pressure. This results in
pure red solids. Single-crystals of [ReO(L1a)(CN)] suitable for
X-ray diﬀraction were obtained by recrystallization from
CH2Cl2–n-hexane.
[ReO(CN)(L1a)] (7a). Color: red. Yield: 93% (29 mg). Anal.
Calcd for C21H23N6OReS2: C, 40.3; N, 13.4; S, 10.3%. Found: C,
40.2; N, 13.2; S, 10.4%. IR (νmax/cm
−1): 2128 w (CuN, cyanido),
1559 vs (CvN), 989 vs (RevO). 1H NMR (CDCl3, ppm): 1.35
(m, 6H, CH3), 3.36 (s, 3H, NCH3), 3.81–3.91 (m, 2H, CH2),
3.95–4.19 (m, 2H, CH2), 7.16–7.23 (m, 3H, Ph), 7.30 (t, J = 7.8
Hz, 2H, Ph), 7.37–7.50 (m, 3H, Ph), 7.78 (d, J = 7.0 Hz, 2H, Ph).
ESI+ MS (m/z, assignment): 627 [M + H]+, 649 [M + Na]+, 665
[M + K]+, 1275 [2M + Na]+.
[ReO(CN)(L1b)] (7b). Color: red. Yield: 81% (25 mg). Anal.
Calcd for C20H27N6OReS2 (617.80): C, 38.9; N, 13.6; S, 10.4.
Found: C, 39.0; N, 13.4; S, 10.6%. IR (νmax/cm
−1): 2122 w
(CuN, cyanido), 1570 vs (CvN), 990 vs (RevO). 1H NMR
(CDCl3, ppm): 1.30–1.35 (m, 6H, CH3), 1.36–1.62 (m, 8H, CH2
azepine), 3.57–3.62 (m, 4H, N–CH2 azepine), 3.82–4.12 (m, 4H,
CH2), 7.32–7.42 (m, 3H, Ph), 7.70 (d, J = 7.0 Hz, 2H, Ph). ESI+
MS (m/z, assignment): 619 [M + H]+, 641 [M + Na]+, 657
[M + K]+.
[ReO(NCS)2(HL1b)] (8b). H2L1b (0.1 mmol) was added to a
solution of (NBu4)[ReOCl4] (0.1 mmol) in 1 mL and stirred for
2 h at room temperature. Then, NH4SCN (0.4 mmol) in 1 mL
MeOH was added and the resulting mixture was stirred for one
more hour. This results in the precipitation of a brown solid
compound, which was filtered oﬀ, washed with MeOH,
n-hexane and dried under vacuum. Single-crystals suitable for
an X-ray study were obtained by recrystallization from CH2Cl2–
MeOH. Color: brown. Yield: 97% (69 mg). Anal. Calcd for
C21H28N7ReS4 (692.95): C, 36.5; N, 13.5; S, 17.7. Found: C,
35.7; N, 13.6; S, 18.1%. IR (νmax/cm
−1): 3089 w (N–H), 2102 vs
(CuN, isothiocyanate), 2081 vs (CuN, isothiocyanato), 1590 vs
(CvN, ligand), 965 s (RevO). 1H NMR (CDCl3, ppm):
1.27–1.35 (m, 6H, CH3), 1.47–1.60 (m, 8H, CH2 azepine),
3.54–3.58 (m, 4H, N–CH2 azepine), 3.90–3.93 (m, 4H, CH2),
7.32–7.37 (m, 3H, Ph), 7.60 (d, J = 7.7 Hz, 2H, Ph). ESI+ MS
(m/z, assignment): 651 [M − NCS]+, 1242 [2M − 3(NCS) − 2H]+,
1301 [2M − 2NCS − H]+.
[ReO(NCS)(L1b)(dmso-κO)] (9b). A sample of [ReO(NCS)2-
(HL1b)] was recrystallized from a DMSO–MeOH (1 : 2) mixture.
Color: purple. Yield: 90% (65 mg). Anal. Calcd for
C22H33N6O2ReS4 (727.99): C, 36.3; N, 11.5; S, 17.6. Found: C,
36.0; N, 11.9; S, 18.0. IR (νmax/cm
−1): 2074 vs (CuN, isothio-
cyanato), 1524 vs (CvN, ligand), 990 (SvO), 971 s (RevO). 1H
NMR (CDCl3, ppm): 1.29 (t, J = 7.2 Hz, 3H, CH3), 1.34 (t, J =
7.0 Hz, 3H, CH3), 1.43–1.63 (m, 8H, CH2 azepine), 2.55 (6H,
CH3 dmso), 3.50–3.63 (m, 4H, NCH2 azepine), 3.88–3.98 (m,
4H, CH2), 7.40–7.55 (m, 3H, Ph), 7.55 (d, J = 6.1 Hz, 2H, Ph).
ESI+ MS (m/z, assignment): 1242 [2M − 2(dmso) − (NCS)]+.
[ReO(N3)(L1b)] (10b). Method A. H2L1b (0.05 mmol) was
added to a solution of (NBu4)[ReOCl4] (0.05 mmol) in 1 mL
MeOH and the mixture was stirred for 1 h at room temp-
erature. Then, a solution of NaN3 (0.15 mmol) in 1 mL MeOH
was added and the stirring was continued for one more hour.
A dark brown precipitate was formed during this time, which
was filtered oﬀ, washed with H2O (3 × 1 mL) and MeOH and
dried in a vacuum. Yield: 75% (24 mg).
Method B. A solution of NaN3 (0.1 mmol) in 2 mL MeOH
was added to a solution of [ReOCl(L1b)] (0.05 mmol) in 0.5 mL
CH2Cl2. The resulting mixture was stirred for a period of 1 h,
during which a brown solid precipitated. This precipitate was
filtered oﬀ and treated as described for method A. Yield: 85%
(27 mg).
Color: dark brown. IR (νmax/cm
−1): 2059 vs (NuN), 1555 s
(CvN), 1512 vs, 1454 s (CvC), 973 m (RevO). 1H NMR
(CDCl3, ppm): 1.21–1.46 (m, 6H, CH3), 1.47–1.70 (m, 8H, CH2
azepine), 3.46–3.63 (m, 4H, N–CH2 azepine), 3.65–4.13 (m, 4H,
CH2), 7.30–7.43 (m, 3H, Ph), 7.61–7.71 (m, 2H, Ph). UV-Vis
(CH2Cl2) [λmax/nm (ε)]: 379 (17 274).
[{ReN(HL1b)}2O] (11b). [ReO(N3)(L1b)] was dissolved in
warm CH2Cl2–MeCN or CH2Cl2–MeOH mixtures and slowly
cooled for crystallization. A change of color from brown to red
was observed and finally a crystalline material was obtained in
almost quantitative yield. Color: red. Anal. Calcd for
C38H56N12ORe2S4 (1197.60): C, 38.1; N, 14.0; S, 10.7%. Found:
C, 37.0; N, 15.1; S, 11.0%. IR (νmax/cm
−1): 1558 (CvN), 1516,
1488 (CvC), 1028 (ReuN), 694 (Re–O–Re′). 1H NMR (CDCl3,
ppm): 1.36 (t, J = 8 Hz, 6H, CH3), 1.41 (t, J = 8 Hz, 6H, CH3),
1.51–1.71 (m, 16H, CH2 azepine + H2O), 3.62–3.71 (m, 8H,
N–CH2 azepine), 3.93–4.11 (m, 8H, CH2), 7.37–7.44 (m, 3H,
Ph), 7.67 (d, J = 8 Hz, 2H, Ph). ESI+ MS (m/z, assignment): 1198
[M + H]+. UV-Vis (CH2Cl2) [λmax/nm (ε)]: 258 (56 886),
395 (22 635).
Synthesis of the mixed-chelate complexes. H2L1 (0.1 mmol)
was added to a solution of (NBu4)[ReOCl4] in 2 mL MeOH and
stirred for 2 h at room temperature. The formed precipitate
was re-dissolved by the addition of 2 mL CH2Cl2. Then,
HPh2btu (0.1 mmol, 33.2 mg) and 3 drops of Et3N were added.
The solution was stirred for one more hour and then the
solvent was removed in a vacuum. The remaining solid was
washed with 1 mL MeOH, filtered and recrystallized from a
minimum amount of a MeOH–CH2Cl2 (1 : 2) mixture. During
cooling in a refrigerator, crystalline precipitates were formed,
which were filtered oﬀ and dried in a vacuum.
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Table 6 X-ray structure data collection and reﬁnement parameters
6a 6b 7a 8b 9b 11b 12b
Formula C21H23N6OReS3 C20H27N6OReS3 C21H23N6OReS2 C21H28N7OReS4 C22H33N6O2ReS4 C40H60Cl4N12ORe2S4 C39H42N7O2ReS3
Fw 657.83 649.86 625.77 708.94 727.99 1367.44 923.18
System Triclinic Monoclinic Monoclinic Monoclinic Triclinic Triclinic Triclinic
Space group P1ˉ P21
a P21/c P21/n P1ˉ P1ˉ P1ˉ
a (Å) 11.208(1) 9.336(5) 9.9759(6) 14.2273(15) 8.5513(6) 8.2495(10) 8.2241(7)
b (Å) 14.146(1) 11.117(5) 10.7569(7) 12.9103(9) 14.4707(11) 12.7783(15) 11.7497(8)
c (Å) 16.761(1) 11.842(5) 21.8824(14) 14.6062(18) 24.0433(17) 13.0830(15) 20.5128(17)
α (°) 101.91(1) 76.669(6) 81.510(9) 93.909(6)
β (°) 90.36(1) 102.937(5) 91.5310(10) 93.9810(10) 83.918(6) 74.673(10) 99.602(7)
γ (°) 111.66(1) 89.555(6) 78.558(10) 93.003(6)
V (Å3) 2406.8(3) 1197.9(10) 2347.4(3) 2676.4(5) 2878.3(4) 1297.0(3) 1945.7(3)
Z 4 2 4 4 4 1 2
ρcalcd
(g cm−3)
1.815 1.802 1.771 1.759 1.680 1.751 1.576
M (mm−1) 5.335 5.358 5.380 4.881 4.542 5.074 3.328
θ Range 1.79 to 29.24 1.76 to 29.22 1.86 to 29.28 1.93 to 29.22 1.75 to 29.30 1.62 to 29.26 1.94 to 29.30
Indices −15 ≤ h ≤ 12, −19 ≤
k ≤ 19, −23 ≤ l ≤ 22
−12 ≤ h ≤ 10, −15 ≤
k ≤ 13, −16 ≤ l ≤ 16
−13 ≤ h ≤ 8, −14 ≤ k
≤ 13, −29 ≤ l ≤ 29
−19 ≤ h ≤ 19, −17 ≤
k ≤ 15, −16 ≤ l ≤ 20
−11 ≤ h ≤ 9, −19 ≤ k
≤ 19, −32 ≤ l ≤ 33
−9 ≤ h ≤ 11, −17 ≤ k ≤
17, −17 ≤ l ≤ 17
−11 ≤ h ≤ 10, −14 ≤ k
≤ 16, −28 ≤ l ≤ 28
Reflections
collected
25 604 8209 14 594 17 994 31 690 13 431 20 481
Unique/Rint 12 813/0.0928 5437/0.0909 6276/0.1038 7171/0.1507 15 314/0.0971 6875/0.0627 10 390/0.0922
Data 12 813 5437 6276 7171 15 314 6875 10 390
Restraints 0 1 0 0 0 0 0
Parameters 584 283 284 309 639 293 472
Abs. corr. Integration Integration Integration Integration Integration Integration None
Tmax/Tmin 0.5461/0.3029 0.7524/0.5070 0.5387/0.1709 0.8647/0.6603 0.5883/0.4135 0.7013/0.3046 —
R1 [I > 2σ(I)] 0.0431 0.0582 0.0601 0.0525 0.0497 0.0407 0.0569
wR2[I > 2σ(I)] 0.0872 0.1356 0.1524 0.1128 0.0952 0.0973 0.1196
GOF on F2 0.824 0.997 1.056 0.791 0.867 1.018 0.979
CCDC code 911727 911728 911729 911730 911731 911732 911733







































































































































[ReO(L1a)(Ph2btu)] (12a). Color: deep purple. Yield: 85%
(80 mg). Anal. Calcd for C41H41N7O2ReS3 (946.20): C, 52.0; N,
10.4; S, 10.2. Found: C, 49.4; N, 9.9; S, 10.3%. 1H NMR (CDCl3,
ppm): 1.14–1.26 (m, 6H, CH3), 3.31 (s, 3H, N–CH3), 3.61–3.71
(m, 2H, N–CH2), 3.89–4.01 (m, 2H, N–CH2), 7.03 (t, J = 7.8 Hz,
Ph), 7.13–7.45 (m, 21H, Ph), 7.72 (dd, 3J = 6.6 Hz, 4J = 2.0 Hz,
2 H, Ph). ESI+ MS (m/z): 932 [M + H]+, 954 [M + Na]+,
970 [M + K]+.
[ReO(L1b)(Ph2btu)] (12b). Color: deep purple. Yield: 89%
(83 mg). Anal. Calcd for C40H45N7O2ReS3 (938.24): C, 51.2; N,
10.5; S, 10.3. Found: C, 50.2; N, 10.4; S, 10.5. 1H NMR (CDCl3,
ppm): 1.16–1.23 (m, 6H, CH3), 1.41 (s, br, 3H, CH2, azepine),
1.49–1.53 (m, 5H, CH2, azepine), 3.52–3.71 (m, 6H, N–CH2,
azepine + NCH2CH3), 3.90–3.98 (m, 2H, N–CH2), 7.01 (t, J =
7.8 Hz, Ph), 7.18–7.55 (m, 16H, Ph), 7.67 (dd, J = 7.6 Hz, 4J =
2.0 Hz, 2H, Ph). ESI+ MS (m/z): 924 [M + H]+.
X-ray crystallography
The intensities for the X-ray determinations were collected on
a STOE IPDS 2T instrument with Mo Kα radiation (λ =
0.71073 Å). Standard procedures were applied for data
reduction and absorption correction. Structure solution and
refinement were performed with SHELXS-97 and SHELXL-97.53
Hydrogen atom positions were calculated for idealized posi-
tions and treated with the “riding model” option of SHELXL.
More details on data collections and structure calculations are
contained in Table 6.
Biochemicals and biological studies
Cell culture conditions. The human MCF-7 breast cancer
cell line was obtained from the American type Culture Collec-
tion (ATCC). This cell line was maintained as a monolayer
culture in L-glutamine containing Dulbecco’s Modified Eagle’s
Medium (DMEM) with 4.5 g L−1 glucose (PAA Laboratories
GmbH, Austria), supplemented with 10% fetal calf serum
(FCS; Gibco, Germany) using 25 cm2 culture flasks in a
humidified atmosphere (5% CO2) at 37 °C. The cell lines were
passaged twice a week after previous treatment with trypsin
(0.05%)/ethylenediamine tetraacetic acid (0.02% EDTA; Boeh-
ringer, Germany). Jurkat cells were purchased from German
Collection of Microorganisms and Cell Culture (Deutsche
Sammlung von Mikroorganismen and Zellkulturen, Braunsch-
weig), DSMZ No ACC 282, LOT 7. The cells were maintained in
a RPMI 1640 (PAA) medium supplemented with 10% fetal calf
serum (PAA), 37 °C, 5% CO2 and maximum humidity.
In vitro chemosensitivity assay. The in vitro testing of the
substances for antitumor activity in adherent growing cell
lines was carried out on exponentially dividing human cancer
cells according to a previously published microtiter assay.54,55
Exponential cell growth was ensured during the whole time of
incubation. Briefly, 100 µL of a cell suspension was placed in
each well of a 96-well microtiter plate at 7200 cells per mL of
culture medium and incubated at 37 °C in a humidified
atmosphere (5% CO2) for 3 d. By removing the old medium
and adding 200 µL of fresh medium containing an adequate
volume of a stock solution of the metal complex, the desired
test concentration was obtained. Cisplatin was dissolved in
dimethylformamide (DMF) while dimethylsulfoxide (DMSO)
was used for all other compounds. Eight wells were used for
each test concentration and for the control, which contained
the corresponding amount of DMF and DMSO, respectively.
The medium was removed after reaching the appropriate incu-
bation time. Subsequently, the cells were fixed with a solution
of 1% (v/v) glutaric dialdehyde in phosphate buﬀered saline
(PBS) and stored under PBS at 4 °C. Cell biomass was deter-
mined by means of a crystal violet staining technique as
described earlier.56 The eﬀectiveness of the complexes is
expressed as corrected T/Ccorr [%] or τ[%] values according to
the following equation:
cytostatic effect : T=Ccorr½% ¼ ½ðT  C0Þ=ðC  C0Þ  100
cytocidal effect : τ½% ¼ ½ðT  C0Þ=C0  100
whereby T(test) and C(control) are the optical densities at 590 nm
of crystal violet extract of the cells in the wells (i.e. the chroma-
tin-bound crystal violet extracted with ethanol (70%) with C0
being the density of the cell extract immediately before treat-
ment. For the automatic estimation of the optical density of
the crystal violet extract in the wells, a microplate autoreader
(Flashscan S 12; Analytik Jena, Germany) was used.
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